One of the best performers on the Australian share market on Tuesday was the LBT Innovations Limited (ASX: LBT) share price.
The medical technology company’s shares finished the day a massive 136% higher at 16.5 cents but were as much as 243% higher to 24 cents at one stage.
Why did the LBT Innovations share price rocket 243% higher?
Investors were fighting to get hold of the company’s shares yesterday after it announced that its 50%-owned joint venture company, Clever Culture Systems, has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its APAS Independence instrument with associated urine analysis module.
According to the release, the FDA clearance is the final regulatory milestone for the instrument, meaning Clever Culture Systems can now commence with sales in the United States.
Management believes that the APAS Independence instrument is the only commercially available instrument for the automatic reading of culture plates in the United States.
In light of this milestone being achieved, the Clever Culture Systems business will now bring forward its US commercialisation and sales activities.
What is the APAS Independence instrument?
The release explains that APAS Independence is a fully automated instrument with the ability to process over 200 culture plates per hour. This is at least three times faster than manual culture plate reading.
The instrument can differentiate culture plates showing bacterial growth from those that are not, without the need for highly skilled microbiologist assistance.
This is key to the clinical utility of the instrument that enables the instrument to be truly autonomous, and without the need for further intervention.
What is the market opportunity?
There are over 5,000 clinical laboratories in the United States, making it the single largest pathology market in the world.
Management estimates that there are more than 1,500 laboratories in this market that exceed the daily culture plate volume that would make the commercial return on investment for the purchase of an APAS Independence attractive.
Previous presentations have suggested a purchase price of ~US$300,000 for APAS Independence, which would make its target market worth around US$450 million.
Finally, if you like exciting small caps then you won't want to miss out on this one that has been tipped for very big things.
A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming. To the tune of an estimated $US22 billion.
Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.
Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.
AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.
Simply click below to learn more on how you can profit from the coming cannabis boom.
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited and Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.